Clinical Guides
Vitiligo
An India-adapted, clinically focused guide to diagnosing vitiligo, screening selectively for associated autoimmunity, choosing site- and age-appropriate treatment, and referring safely for phototherapy, systemic therapy or surgery while addressing psychosocial harm.
MedNext Academy | 16 min read
Vitiligo
An India-adapted, clinically focused guide to diagnosing vitiligo, screening selectively for associated autoimmunity, choosing site- and age-appropriate treatment, and referring safely for phototherapy, systemic therapy or surgery while addressing psychosocial harm.
Summary
Vitiligo is a chronic, acquired AUTOIMMUNE disorder of pigmentation characterised by the progressive destruction of MELANOCYTES, resulting in well-demarcated patches of DEPIGMENTED (chalk-white) skin. It is the most common depigmenting disorder, affecting approximately 0.5-2% of the world's population.
**Pathophysiology:** - The fundamental process is AUTOIMMUNE DESTRUCTION of melanocytes — CD8+ cytotoxic T-lymphocytes target and destroy melanocytes in the skin - The trigger for this autoimmune attack is incompletely understood, but involves: (a) Genetic susceptibility — multiple genes (NLRP1, CTLA4, HLA-A2, TYR, PTPN22) are associated. ~20% of patients have a family history. (b) Oxidative stress — melanocytes in vitiligo patients have increased susceptibility to oxidative damage (hydrogen peroxide accumulation). (c) Environmental triggers — skin trauma (Koebner phenomenon), sunburn, chemical exposure (phenols, catechols), emotional stress, infections - Vitiligo is associated with OTHER AUTOIMMUNE diseases: Autoimmune thyroid disease (Hashimoto's, Graves' — the MOST COMMON association, ~15-25% of vitiligo patients), type 1 diabetes, pernicious anaemia (B12 deficiency), Addison's disease, alopecia areata, rheumatoid arthritis
**Clinical Types:**
**1. Non-segmental vitiligo (NSV — 85-90% of cases):** - The MOST COMMON type. Bilateral, usually SYMMETRIC distribution. Tends to be progressive over time - Subtypes: Generalised (the most common NSV pattern — widely distributed, often symmetric patches), acrofacial (fingers, toes, and face — perioral, periocular), universal (>80% body surface depigmented — rare), mucosal (oral and genital mucosa) - Common sites: Face (especially perioral and periocular), hands and feet (acral), genitalia, axillae, groin, knees, elbows, nipples — areas subject to friction and trauma (Koebner phenomenon)
**2. Segmental vitiligo (SV — 10-15%):** - UNILATERAL, confined to one segment (dermatome) of the body. Does NOT cross the midline - Rapid onset, then STABILISES (stops spreading) relatively quickly (usually within 1-2 years) - More common in CHILDREN - LESS associated with other autoimmune diseases - Responds well to surgical treatment (melanocyte transplantation) because the disease stabilises
**Key Clinical Features:** - Patches are CHALK-WHITE (complete depigmentation — melanocytes are ABSENT, not just reduced). Under WOOD'S LAMP, vitiligo patches show BRIGHT CHALKY-WHITE fluorescence with sharp margins (enhanced contrast) - Well-demarcated borders (sharp transition from depigmented to normally pigmented skin) - Hair within vitiligo patches may also become WHITE (leukotrichia/poliosis) — this suggests destruction of melanocyte stem cells in the hair follicle and indicates a POORER prognosis for repigmentation - No scale, no altered texture — the skin surface is NORMAL (just depigmented) - Usually ASYMPTOMATIC (no itch, no pain)
How Common Is It?
- Global prevalence: 0.5-2% of the population (~50-100 million people)
- Can develop at ANY age, but ~50% of cases begin before age 20
- Equal prevalence in males and females (though women seek treatment more frequently)
- No racial predilection — affects all ethnicities equally, but is MORE VISIBLE and more psychosocially impactful in DARKER skin tones
In India: - India has one of the HIGHEST prevalences of vitiligo globally — estimated at 1-8.8% depending on the region (some Gujarat studies report prevalence >4%) - PSYCHOSOCIAL IMPACT: Vitiligo carries PROFOUND social stigma in India — far greater than in Western countries. It is colloquially called 'safed daag' (white spots) or 'leucoderma'. The stigma includes: Marriage discrimination (vitiligo is still listed in some Indian personal laws as a ground for divorce or annulment. Matrimonial advertisements frequently specify 'no leucoderma'), social ostracism and isolation, employment discrimination, confusion with LEPROSY (which also causes hypopigmented patches — the leprosy stigma compounds the vitiligo stigma), depression, anxiety, and suicidal ideation (rates are significantly higher in Indian vitiligo patients than in Western cohorts) - CONFUSION WITH LEPROSY: In India, where leprosy is still prevalent, vitiligo is frequently confused with leprosy by the public. This compounds the stigma enormously. Key distinction: vitiligo = depigmented (white) + NORMAL SENSATION + no nerve thickening. Leprosy = hypopigmented (not white) + LOSS OF SENSATION + thickened nerves - TRADITIONAL REMEDIES: Many Indian patients try traditional and Ayurvedic remedies (Bakuchi/Psoralea seeds, neem, turmeric, dietary restrictions) before or alongside conventional treatment. Bakuchi (Psoralen corylifolia) contains psoralen — the basis of PUVA therapy — and has historical use in Indian traditional medicine for vitiligo - AUTOIMMUNE THYROID DISEASE: Given the high co-occurrence, ALL Indian vitiligo patients should be screened for thyroid disease (TSH at diagnosis and periodically)
Risk Factors
Vitiligo is an acquired disorder of melanocyte loss with autoimmune, genetic and environmental contributions. A family history, other autoimmune disease, thyroid disease, alopecia areata, type 1 diabetes or pernicious anaemia increases clinical suspicion but is not required. New lesions may follow friction, burns, cuts or other trauma (Koebner phenomenon). Ask about occupational or household exposure to phenolic or catecholic chemicals, because chemical leukoderma can mimic or coexist with vitiligo. Do not attribute the condition to food combinations, poor hygiene, contagion or personal fault.
Risk assessment includes activity, body sites, mucosal or acral involvement, leukotrichia, segmental distribution, age at onset and effect on school, work, relationships and mental health. Children may be particularly affected by bullying and family pressure. Pregnancy, breastfeeding and plans for conception matter before topical, phototherapy or systemic choices; treatment goals may reasonably be stabilisation, repigmentation, camouflage or acceptance. A patch with altered sensation, scale, inflammation or an unusual solitary lesion is a diagnostic warning, especially in India where leprosy remains an important alternative. Rapidly progressive disease, ocular or auditory symptoms and severe distress lower the threshold for specialist referral.
Diagnosis
Examination
Perform a focused examination of the relevant body sites, document distribution, morphology, severity and complications, and assess general or systemic signs when indicated.
History
Ask about onset, duration, progression, relevant exposures, medicines, family history, pregnancy or breastfeeding, prior self-treatment and the effect on daily life. Clarify symptoms that change urgency and record what has already been tried, including dose, duration, adherence and adverse effects.
Clinical Assessment
- **Clinical diagnosis**: Vitiligo is diagnosed by its characteristic CHALK-WHITE, well-demarcated patches with normal skin texture
- **Wood's lamp examination**: Enhances the contrast between depigmented and normal skin. Vitiligo shows BRIGHT CHALKY-WHITE fluorescence. Useful for: Confirming depigmentation (vs hypopigmentation), detecting early or subclinical lesions not visible to the naked eye, assessing extent of disease
Differentials
- **Pityriasis versicolor**: HYPOPIGMENTED (not depigmented). Fine scale. Golden-yellow fluorescence under Wood's lamp. KOH shows 'spaghetti and meatballs'. Responds to antifungals
- **Pityriasis alba**: Hypopigmented patches on the FACE of children. Mild scaling. Associated with atopic dermatitis. Self-limiting
- **Post-inflammatory hypopigmentation**: Follows an inflammatory skin condition (eczema, psoriasis). Distribution corresponds to the prior dermatosis
- **Leprosy (Hansen disease)**: Hypopigmented patch with LOSS OF SENSATION. Thickened peripheral nerves. Crucial differential in India
- **Chemical leukoderma**: Depigmentation caused by contact with phenolic compounds (found in some rubber products, hair dyes, adhesives). Occupational exposure history. Distribution matches the contact area
- **Piebaldism**: CONGENITAL (present from birth). White forelock. Stable (doesn't progress). Autosomal dominant (KIT gene mutation). NOT autoimmune
- **Idiopathic guttate hypomelanosis**: Multiple small (2-5mm), well-defined, hypopigmented macules on sun-exposed skin (forearms, shins) of older adults. NOT depigmented. Photodamage-related
Investigations
- **Thyroid function tests (TSH)**: Screen ALL vitiligo patients at diagnosis. Repeat periodically (annually or if symptoms develop). Autoimmune thyroid disease is present in ~15-25%
- **Anti-thyroid antibodies** (anti-TPO, anti-thyroglobulin): If TSH is abnormal, or to identify subclinical autoimmune thyroid disease
- **Full blood count**: Screen for pernicious anaemia (associated autoimmune condition)
- **Fasting glucose/HbA1c**: Screen for type 1 diabetes
- **Skin biopsy**: Rarely needed (clinical diagnosis is usually sufficient). Histology shows ABSENCE of melanocytes (confirmed by Melan-A or S100 immunostaining). Useful if diagnosis is uncertain
Differential Diagnosis
Vitiligo usually produces well-demarcated depigmented macules or patches with normal surface and sensation. Pityriasis versicolor causes fine scale and may be hypo- or hyperpigmented; a potassium hydroxide examination can help when scale is present. Post-inflammatory hypopigmentation follows eczema, psoriasis, injury or infection. Chemical leukoderma is linked to repeated contact with phenolic or catecholic compounds and may be confetti-like. Piebaldism and Waardenburg syndrome are congenital patterns, often with a white forelock or stable distribution from early life.
Leprosy must be actively excluded when a patch is hypopigmented or erythematous with sensory loss, anhidrosis, hair loss or nerve thickening. Tinea corporis, nevus depigmentosus, halo naevus, hypopigmented mycosis fungoides and idiopathic guttate hypomelanosis may enter the differential according to morphology and age. Ocular inflammation, hearing symptoms, neurologic features or widespread depigmentation can indicate a broader inflammatory syndrome or require a different pathway. Wood lamp examination can accentuate depigmentation but does not replace history, sensation testing and examination of nerves, hair and mucosa. Biopsy is reserved for atypical or uncertain cases and should be arranged by dermatology.
Management
General Principles
- **SUN PROTECTION**: Depigmented skin has NO melanin protection → highly susceptible to SUNBURN. SPF 30+ broad-spectrum sunscreen on exposed depigmented areas DAILY. Protective clothing. This is both a protective measure and cosmetic (prevents tanning of surrounding normal skin, which increases the contrast with depigmented patches)
- **Counselling and psychological support**: ESSENTIAL in Indian practice given the severe psychosocial impact. Address misconceptions (vitiligo is NOT contagious, NOT caused by diet, NOT leprosy). Referral for psychological support if needed
- **Cosmetic camouflage**: Specialised camouflage make-up or self-tanning products to cover depigmented patches. Can significantly improve quality of life while awaiting treatment response
Topical Treatment — First-Line for LOCALISED Disease (<20% BSA)
**Topical corticosteroids:** - **Mometasone 0.1% cream or betamethasone valerate 0.1% cream**: Applied OD for 3-6 months. Effective for SMALL, recent-onset patches, particularly on the face and trunk. Repigmentation rates: ~50-60% with potent topical steroids - Use MODERATE potency on the FACE (mometasone). Use POTENT steroids on the body (betamethasone, clobetasol) - Monitor for steroid side effects (atrophy, striae, telangiectasia) with prolonged use. Consider 'pulse therapy' (apply for 2 weeks, then 2 weeks off) - Cost: ₹30-100 per tube
**Topical calcineurin inhibitors (STEROID-SPARING — preferred for face and neck):** - **Tacrolimus 0.1% ointment [Protopic]**: Applied BD. Effective for facial vitiligo (WHERE repigmentation is most likely to occur — the face has a rich melanocyte reservoir in hair follicles) - **Pimecrolimus 1% cream [Elidel]**: Applied BD. Alternative to tacrolimus - NO risk of skin atrophy (unlike steroids) → can be used long-term on the face - Cost: ₹200-500 per tube
Phototherapy — For WIDESPREAD Disease (>20% BSA) or Localised Disease Not Responding to Topicals
**Narrow-band UVB (NB-UVB) — FIRST-LINE phototherapy:** - The GOLD STANDARD treatment for widespread vitiligo. Sessions 2-3× per week for 6-12 MONTHS (minimum). Repigmentation occurs gradually — starting from the hair follicles (perifollicular repigmentation — tiny brown dots appearing within the white patches) - Repigmentation rates: ~50-70% achieve some repigmentation (face and trunk respond best; hands, feet, and lips respond poorly) - Available in dermatology departments across India. Home NB-UVB units are also available - Side effects: Sunburn-like erythema (dose must be carefully titrated), long-term theoretical skin cancer risk (very low with NB-UVB)
**PUVA (Psoralen + UVA):** - Oral psoralen (methoxsalen 0.4mg/kg) taken 2 hours before UVA exposure. Sessions 2-3× per week - Less commonly used now (NB-UVB has replaced PUVA as first-line) due to more side effects (nausea from oral psoralen, phototoxicity, higher skin cancer risk than NB-UVB) - Topical PUVA (psoralen solution applied to the skin before UVA) can be used for localised patches
Surgical Treatment — For STABLE, Localised Vitiligo Not Responding to Medical Treatment
- **Melanocyte transplantation**: Autologous melanocytes are harvested from a normally pigmented donor site (usually the thigh or buttock), processed (either as a cell suspension or as split-thickness grafts), and transplanted to the depigmented area
- Best results in SEGMENTAL vitiligo and STABLE non-segmental vitiligo (disease must be stable — no new lesions for ≥1 year)
- Available at tertiary dermatology centres in India. Several Indian centres (AIIMS, PGI Chandigarh, etc.) are world leaders in melanocyte transplant techniques
- Repigmentation rates: >80% in properly selected patients (stable disease, non-acral sites)
Treatment choices must be agreed with dermatology when disease is extensive, rapidly active, paediatric, pregnancy-associated or resistant. Topical therapy should not be applied to eyelids, mucosa or thin skin without specific advice; phototherapy requires eye protection and a supervised schedule. Systemic corticosteroids, JAK inhibitors and surgery are specialist decisions, not routine primary-care prescriptions.
Prescribing Information
Tacrolimus 0.1% Ointment [Protopic]
- Apply BD to affected areas (particularly effective on the FACE)
- Steroid-sparing. No atrophy risk. Safe for long-term use
- Burning/stinging sensation on initial application (usually settles within a week)
- Combine with SUN EXPOSURE or NB-UVB for enhanced repigmentation
- Cost: ₹200-500 per tube
Mometasone 0.1% Cream
- Apply OD to affected areas for 3-6 months (pulse: 2 weeks on, 2 weeks off)
- Moderate-potent steroid. Suitable for face (short-term) and body
- Monitor for steroid atrophy with prolonged use
- Cost: ₹50-150 per tube
Methoxsalen (8-MOP) Tablets
- Dose: 0.4mg/kg taken 2 hours BEFORE UVA exposure
- For PUVA therapy. Photosensitises the skin
- Side effects: Nausea, phototoxicity. Wear UV-protective sunglasses for 24 hours after dose
- Cost: ₹50-100 per session
When to Refer
Refer to dermatology when the diagnosis is uncertain, lesions are rapidly spreading, disease involves eyelids, lips, genital skin or extensive body surface, there is leukotrichia or scarring concern, or first-line treatment has not achieved a shared goal. Children, pregnant or breastfeeding patients and people considering phototherapy, systemic corticosteroids, JAK inhibitors or surgical grafting need specialist-led decisions. Urgent assessment is appropriate for sensory loss or thickened nerves suggesting leprosy, painful red eyes or visual change, hearing symptoms, widespread acute inflammation or severe medication reactions. Ask about distress, bullying, avoidance, depression and self-harm; involve mental-health services promptly when risk is present. Referral letters should describe activity, sites, sensation, Wood-lamp findings if available, prior products and durations, comorbidity, pregnancy status, patient goals and access barriers. Camouflage advice and peer support can begin while has been reviewed by the MedNext Clinical Team.
Red Flags
- **Rapidly progressive vitiligo** (new patches appearing frequently, existing patches expanding rapidly): → Consider systemic treatment — oral mini-pulse steroids (dexamethasone 2.5mg on 2 consecutive days per week for 3-6 months) to halt progression. Refer to dermatologist
- **Vitiligo + symptoms of thyroid disease** (fatigue, weight change, cold/heat intolerance): → Check TSH urgently. Autoimmune thyroid disease is the most common association (~15-25%)
- **Depigmented patch with LOSS OF SENSATION**: → This is NOT vitiligo — consider LEPROSY. Test sensation (cotton wool, pin). Examine peripheral nerves. Slit-skin smear. Critical differential in India
- **Vogt-Koyanagi-Harada (VKH) syndrome**: → Vitiligo + uveitis + hearing loss + meningitis. Autoimmune condition targeting melanocytes in skin, eyes, ears, and meninges. Ophthalmology referral urgently if eye symptoms (blurred vision, eye pain, photophobia)
- **Depigmentation around a melanocytic naevus ('halo naevus')**: → Ring of depigmentation around a mole. Usually benign (autoimmune destruction of the naevus — can be associated with vitiligo elsewhere). BUT in adults, exclude MELANOMA with halo regression (a melanoma can develop a halo of depigmentation as the immune system attacks it). Dermoscopy + biopsy if atypical
- **Chemical/occupational leukoderma**: → Exposure to phenolic compounds (rubber industry, adhesives, cleaning agents). Depigmentation at the contact site. Important to identify and remove the exposure. Can be confetti-like in pattern
Indian Clinical Context
Vitiligo management in India is uniquely challenging due to the profound psychosocial dimensions:
Stigma and discrimination: The social stigma of vitiligo in India is among the worst in the world. 'Safed daag' is deeply feared. Marriage prospects are severely affected — matrimonial rejections on the basis of vitiligo are widespread and normalised. The Persons with Disabilities Act (2016) does not include vitiligo, though advocacy groups are campaigning for its inclusion. Some Indian personal laws still list 'leucoderma' as grounds for divorce. Dermatologists in India must address the psychosocial dimensions alongside the medical treatment — simply prescribing topical therapy without addressing the patient's distress is inadequate.
Leprosy confusion: India accounts for ~50% of the world's new leprosy cases. The historical association between white skin patches and leprosy persists in public consciousness, compounding the stigma of vitiligo. Every clinician should actively differentiate the two and educate patients and their families. Key teaching point: vitiligo has NORMAL SENSATION, leprosy has LOSS OF SENSATION.
Surgical expertise: India is a GLOBAL LEADER in melanocyte transplantation techniques for vitiligo. Several Indian centres (AIIMS Delhi, PGI Chandigarh, medical colleges in Gujarat) have pioneered and refined non-cultured melanocyte-keratinocyte transplant procedures (NCES — non-cultured epidermal cell suspension). These procedures are effective, relatively affordable (₹5,000-20,000 depending on area), and available at multiple tertiary centres.
Traditional medicine: Bakuchi (Psoralea corylifolia) seeds have been used in Ayurvedic and Unani medicine for vitiligo for centuries. Bakuchi contains psoralen — the photosensitising agent used in PUVA therapy. While traditional use predates modern phototherapy, unregulated use of bakuchi oil/paste can cause severe phototoxic reactions. Patients should be counselled about supervised phototherapy rather than self-treatment.
Dietary myths: Many Indian patients believe that certain food combinations ('viruddha ahara') cause vitiligo — particularly combining milk with fish, or sour foods. There is NO scientific evidence for any dietary cause of vitiligo. These myths cause unnecessary dietary restrictions and guilt.
NMC Competency Mapping
The guide supports NMC dermatology and AETCOM outcomes: describe normal and abnormal pigmentation, examine morphology and distribution, test sensation and peripheral nerves, construct a differential diagnosis and communicate without stigma. Learners should distinguish segmental from non-segmental patterns, recognise activity and prognostic sites, screen selectively for thyroid or other autoimmune disease when clinically justified, and explain that vitiligo is not contagious. Competence includes safe counselling about topical steroids, calcineurin inhibitors, phototherapy, pregnancy and referral; it does not permit unsupervised systemic immunomodulation, JAK-inhibitor prescribing or melanocyte transplantation. The patient’s goals may include stabilisation, repigmentation, camouflage or acceptance, and mental-health assessment is part of good care. Examination answers should pair morphology with exclusion of leprosy and other mimics rather than naming a treatment from a photograph alone.
Key Exam Pearls for NEET PG
- Vitiligo: AUTOIMMUNE destruction of melanocytes by CD8+ T-cells. Most common depigmenting disorder
- Clinical: CHALK-WHITE, well-demarcated patches. NORMAL skin texture. No scale. No sensation change
- Wood's lamp: BRIGHT CHALKY-WHITE fluorescence (vs pityriasis versicolor = golden-yellow)
- Types: Non-segmental (85-90%, bilateral, symmetric, progressive) vs segmental (10-15%, unilateral, stabilises)
- Koebner phenomenon: New vitiligo at sites of TRAUMA (friction, cuts, burns)
- Leukotrichia (white hair in patches): Poor prognosis for repigmentation (follicular melanocyte stem cells destroyed)
- Associations: Autoimmune thyroid (15-25% — SCREEN ALL), T1DM, pernicious anaemia, Addison's, alopecia areata
- Treatment localised: Topical steroids (mometasone OD) or calcineurin inhibitors (tacrolimus BD — preferred for FACE)
- Treatment widespread: NB-UVB phototherapy (gold standard). 2-3×/week × 6-12 months. Face responds best, acral worst
- Surgical: Melanocyte transplant for STABLE disease. India = global leader in NCES technique
- Oral mini-pulse steroids: Dexamethasone 2.5mg × 2 days/week for rapidly progressive disease
- Repigmentation pattern: PERIFOLLICULAR (tiny brown dots from hair follicle melanocyte reservoir)
- Distinguish from: Pityriasis versicolor (hypopigmented + scale), leprosy (hypopigmented + anaesthetic), piebaldism (congenital, white forelock)
- India: Severe psychosocial stigma ('safed daag'). Confusion with leprosy. Marriage discrimination. Dietary myths unfounded
Frequently Asked Questions
Is vitiligo contagious, and can household contact spread it?
NO — vitiligo is absolutely NOT contagious. You CANNOT catch vitiligo from someone who has it, no matter how close the contact. Vitiligo is an AUTOIMMUNE condition — the person's own immune system attacks and destroys their melanocytes (pigment-producing cells). It is not caused by a virus, bacterium, or any transmissible agent. You cannot get it from: Touching someone with vitiligo, sharing food, clothes, or utensils, living in the same household, sexual contact, swimming in the same pool. This misconception is particularly harmful in India, where vitiligo ('safed daag') carries severe social stigma. People with vitiligo are sometimes shunned, refused employment, or rejected in marriage — based entirely on the false belief that the condition is contagious or 'impure'. The reality is that vitiligo is in the same category of diseases as thyroid disease and type 1 diabetes — it is an autoimmune condition, not an infection. Spreading awareness about this is one of the most important things healthcare providers can do.
Can vitiligo be cured, and what can treatment realistically achieve?
Currently, there is NO PERMANENT CURE for vitiligo — it is a chronic autoimmune condition. However, EFFECTIVE TREATMENTS exist that can achieve significant REPIGMENTATION in many patients. WHAT TREATMENT CAN ACHIEVE: (a) REPIGMENTATION — returning colour to the white patches. Topical treatments (steroids, tacrolimus) achieve repigmentation in 50-60% of localised patches. NB-UVB phototherapy achieves some repigmentation in 50-70% of patients. Melanocyte transplantation achieves >80% repigmentation in selected patients (stable disease). (b) STABILISATION — stopping the disease from spreading further. Oral mini-pulse steroids can halt progression. IMPORTANT CAVEATS: (1) FACE responds best to treatment (rich melanocyte reservoir in hair follicles). Hands, feet, and lips respond POORLY. (2) Repigmentation takes TIME — expect 6-12 months minimum of consistent treatment before seeing significant results. (3) RELAPSE is possible — even after successful repigmentation, the patches can recur. Maintenance therapy (topical calcineurin inhibitors, periodic phototherapy) can reduce relapse risk. (4) Leukotrichia (white hair within patches) is a marker of POOR response — the melanocyte stem cells in the hair follicle have been destroyed, so repigmentation from the follicular reservoir is unlikely. EMERGING TREATMENTS: JAK inhibitors (ruxolitinib cream — FDA-approved for vitiligo in 2022) represent a significant advance. They work by blocking the JAK-STAT pathway that drives the autoimmune attack on melanocytes. Availability and cost in India are currently limiting factors.
Does diet cause or cure vitiligo?
NO — there is NO scientific evidence that any specific food or food combination causes vitiligo, and no diet has been proven to cure it. COMMON DIETARY MYTHS (particularly in India): (1) 'Milk + fish combination causes vitiligo' — FALSE. No scientific basis. (2) 'Sour foods (citrus, curd, pickles) cause or worsen vitiligo' — FALSE. No evidence. (3) 'White foods should be avoided' — FALSE. This is sympathetic magic, not science. (4) 'Vitamin C worsens vitiligo' — FALSE. Vitamin C does NOT worsen vitiligo. (5) 'Non-vegetarian food causes vitiligo' — FALSE. These myths cause significant harm: unnecessary dietary restrictions, nutritional deficiencies (particularly in children whose diet is unnecessarily restricted), guilt and self-blame, and delay in seeking effective medical treatment. WHAT IS ACTUALLY TRUE: Vitiligo is an AUTOIMMUNE condition. It is NOT caused by food, lifestyle, or karma. A BALANCED, NUTRITIOUS diet supports overall health and immune function, which is beneficial for any autoimmune condition. Specific nutrients worth ensuring adequacy: Vitamin D (immunomodulatory — deficiency is common in Indian vitiligo patients), vitamin B12 and folic acid (some studies suggest supplementation may enhance phototherapy response), antioxidants (vitamin C, vitamin E, selenium — may help counteract oxidative stress in melanocytes). BOTTOM LINE: Eat a normal, balanced diet. Do not restrict any foods based on vitiligo myths. If you want to optimise nutrition, ensure adequate vitamin D, B12, and folic acid.
Should I get my child tested for thyroid disease if they have vitiligo?
YES — thyroid screening is recommended for ALL patients with vitiligo, including children. Autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease) is the MOST COMMON autoimmune condition associated with vitiligo, affecting approximately 15-25% of vitiligo patients. WHY SCREEN? (a) Autoimmune thyroid disease is COMMON in vitiligo (15-25% prevalence — far higher than the general population). (b) Thyroid disease can be SUBCLINICAL (no symptoms) in the early stages — detected only by blood tests. (c) UNTREATED thyroid disease can cause significant problems: Hypothyroidism → fatigue, weight gain, constipation, poor school performance in children, growth delay. Hyperthyroidism → weight loss, tremor, anxiety, tachycardia. (d) TREATMENT of thyroid disease is straightforward and highly effective once diagnosed. WHAT TESTS? (1) TSH (thyroid-stimulating hormone) — the single most useful screening test. Normal TSH effectively rules out thyroid dysfunction. (2) Anti-TPO antibodies (anti-thyroid peroxidase) — if positive, indicates autoimmune thyroid disease even if TSH is currently normal (the patient may develop thyroid dysfunction in the future and should be monitored). WHEN TO TEST: At the time of VITILIGO DIAGNOSIS (baseline). Then ANNUALLY (or sooner if symptoms develop). This is recommended by the IADVL, BAD, and most international vitiligo guidelines.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic